Minja Mladenović
Minja Mladenović publishes mostly in Biomedical Engineering, Molecular Biology and Materials Chemistry, on topics such as Nanoplatforms for cancer theranostics, Nanoparticle-Based Drug Delivery and Advanced biosensing and bioanalysis techniques.
- World rank
- #3,191,594 of 7,710,434 ranked researchers
- Rank in Serbia
- #3,113 of 18,168
- Works
- 16
- Citations
- 619
- Citations per work
- 38.7
What does Minja Mladenović research?
Minja Mladenović's work is mostly in Materials Science (33%), Engineering (27%), Biochemistry, Genetics and Molecular Biology (20%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Physical Sciences1064.5%
- Materials Science533.4%
- Engineering426.7%
- Chemical Engineering02.2%
- Chemistry02.2%
- Life Sciences320.0%
- Everything else215.5%
- 1Biomedical Engineering27% of their works
- 2Molecular Biology20% of their works
- 3Materials Chemistry18% of their works
- 4Biomaterials16% of their works
- 5Inorganic Chemistry2% of their works
- 6Catalysis2% of their works
Research topics
- Nanoplatforms for cancer theranostics
- Nanoparticle-Based Drug Delivery
- Advanced biosensing and bioanalysis techniques
- Advanced Biosensing Techniques and Applications
- Biosensors and Analytical Detection
- Mesoporous Materials and Catalysis
- RNA Interference and Gene Delivery
- Molecular Communication and Nanonetworks
Which keywords describe Minja Mladenović's research?
The keywords of their largest research topics: Nanoparticles, Tumor Targeting, Drug Delivery, Biosensors, Cancer Therapy, Nanocarriers, Photothermal Therapy and Reactive Oxygen Species.
- siRNA Delivery
- Nanonetworks
- Protein Microarrays
- Nanocomposite Materials
- Loop-Mediated Isothermal Amplification
- Self-Assembly
- Reactive Oxygen Species
- Nanocarriers
- Biosensors
- Tumor Targeting
- Nanoparticles
- Drug Delivery
- Cancer Therapy
- Photothermal Therapy
- DNA nanotechnology
- High-Throughput Analysis
- Mesoporous Materials
- Paper-Based Microfluidics
- Molecular Communication
- RNA Interference
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 20 words, with their numbers
- Nanoparticles143 topics
- Tumor Targeting102 topics
- Drug Delivery82 topics
- Biosensors72 topics
- Cancer Therapy51 topic
- Nanocarriers51 topic
- Photothermal Therapy51 topic
- Reactive Oxygen Species51 topic
- DNA nanotechnology41 topic
- Self-Assembly41 topic
- High-Throughput Analysis31 topic
- Loop-Mediated Isothermal Amplification31 topic
- Mesoporous Materials31 topic
- Nanocomposite Materials31 topic
- Paper-Based Microfluidics31 topic
- Protein Microarrays31 topic
- Molecular Communication21 topic
- Nanonetworks21 topic
- RNA Interference21 topic
- siRNA Delivery21 topic
Where does Minja Mladenović work?
Minja Mladenović's main affiliation in the publication record is BioSense Institute, Serbia.
How many publications and citations does Minja Mladenović have?
OpenAlex counts 16 works and 619 citations for Minja Mladenović, an h-index of 7, ranking #3,191,594 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Minja Mladenović. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.